Clinical Trial Update: Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reports efficacy and safety data for subcutaneous TEV-48125 used preventively in episodic migraine, spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• TEV-48125

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Migraine | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-07-08